Lipaglyn Tablet 10's

Lipaglyn Tablet is an insulin sensitiser used to treat diabetic dyslipidaemia/hypertriglyceridemia in type-2 diabetic patients, which is not controlled by statins (lipid-lowering agents) alone. Lipaglyn Tablet has both lipid and glucose-lowering effects in a single molecule, thereby helping lower blood triglycerides and blood glucose levels. Diabetic dyslipidaemia is characterised by increased triglyceride levels, low-density lipoproteins (LDL) and decreased high-density lipoprotein (HDL) levels. This condition is common in people with type-2 diabetes mellitus.
 
Lipaglyn Tablet contains ‘Saroglitazar’, which has dual Peroxisome Proliferator-Activated Receptor (PPAR)-α/γ agonist having a strong PPAR-alpha effect and moderate PPAR-gamma effect. PPAR-alpha reduces the synthesis and secretion of triglycerides and increases lipolysis and hepatic oxidation of fatty acids. It also induces an increase in the synthesis of HDL cholesterol. PPAR-gamma reduces the metabolic burden on the liver and muscle and promotes glucose utilisation. It improves post-absorptive insulin-mediated suppression of hepatic glucose output. Thereby, Lipaglyn Tablet helps in lowering blood triglycerides and blood glucose levels.
 
You are advised to take Lipaglyn Tablet for as long as your doctor has prescribed it, depending on your medical condition. In some cases, you may experience certain common side effects, such as stomach inflammation, nausea, vomiting, weakness, chest discomfort, dizziness, and fever. Most of these side effects do not require medical attention and will resolve gradually over time. However, you are recommended to consult your doctor if you experience these side effects persistently.
 
Consult your doctor if you are pregnant. It is not known if Lipaglyn Tablet is excreted into breastmilk; therefore, nursing mothers should avoid taking Lipaglyn Tablet . Lipaglyn Tablet should not be given to children as safety and effectiveness have not been established. Lipaglyn Tablet should be used with caution in patients with kidney or liver impairment and in elderly patients. Avoid alcohol consumption while taking Lipaglyn Tablet as it might cause unpleasant side effects. Lipaglyn Tablet might cause dizziness, so drive with caution. Inform your doctor about all the medications you are taking and your health condition to rule out any unpleasant side effects.

Lipaglyn Tablet is an insulin sensitiser used to treat diabetic dyslipidaemia/hypertriglyceridemia in type-2 diabetes, which is not controlled by statins alone. Lipaglyn Tablet has demonstrated a reduction of triglycerides (TG), Low-Density Lipoprotein (LDL) cholesterol, non-high-density Lipoprotein (non-HDL) cholesterol, Very Low-Density Lipoprotein (VLDL) cholesterol, and an increase in HDL cholesterol. It has also shown glycemic indices by lowering the fasting plasma glucose and glycosylated haemoglobin in diabetic patients. Lipaglyn Tablet has dual Peroxisome Proliferator-Activated Receptor (PPAR)-α/γ agonist having strong PPAR-alpha effect and moderate PPAR-gamma effect. PPAR-alpha reduces the synthesis and secretion of triglycerides and increases lipolysis and hepatic oxidation of fatty acids. It also induces an increase in the synthesis of HDL cholesterol. PPAR-gamma reduces the metabolic burden on the liver and muscle, promotes glucose utilisation, and improves post-absorptive insulin-mediated suppression of hepatic glucose output. Lipaglyn Tablet has both lipid and glucose-lowering effects in a single molecule; this helps in lowering blood triglycerides and blood glucose levels as well. It also helps in improving insulin resistance. Lipaglyn Tablet offers a superior safety profile, greater efficacy on lipid regulation, and excellent glycaemic control.

• Gastritis (stomach inflammation)
• Nausea
• Vomiting
• Asthenia (weakness)
• Chest discomfort
• Dizziness
• Pyrexia (fever)

Do not take Lipaglyn Tablet if you are allergic to any of the components. Inform your doctor if you notice rapid weight gain. Consult your doctor before taking Lipaglyn Tablet if you are pregnant. It is not known if Lipaglyn Tablet is excreted into breastmilk; therefore, nursing mothers should avoid taking Lipaglyn Tablet . Lipaglyn Tablet should not be given to children as safety and effectiveness have not been established. Lipaglyn Tablet might cause dizziness, so drive with caution. Avoid alcohol consumption while taking Lipaglyn Tablet as it might cause unpleasant side-effects. Lipaglyn Tablet should be used with caution in patients with type-2 diabetes having cardiovascular disease.

Drug-Drug Interactions: No interactions found/established.

Drug-Food Interactions: No interactions found/established.

Drug-Disease Interactions: No interactions found/established.

• Follow a cholesterol-lowering diet.

• Exercise regularly. It helps in maintaining proper weight and lowers cholesterol.

• Limit salt and sugar intake.

• Avoid smoking and alcohol consumption. 

• Choose healthy fats and cut down on trans-fat.

• Include omega-3 fatty acids, fibre-rich food, fruits and vegetables.

• Get active by doing any physical activity such as swimming, brisk walking or jogging. Take stairs instead of elevators/lifts.

• Try eating food at regular intervals. Do not skip meals. Also, try not to overeat.

• Follow a healthy diet and walk for at least 45 minutes to complement treatment with Lipaglyn Tablet .

• Rest properly, avoid stress by doing meditation or yoga.

Diabetic dyslipidaemia/hypertriglyceridemia: Diabetic dyslipidaemia, also known as hypertriglyceridemia, is characterised by increased triglyceride levels, low-density lipoproteins (LDL) and decreased high-density lipoprotein (HDL) levels. This condition is common in people with type-2 diabetes mellitus. It is one of the major risk factors for cardiovascular disease in diabetic patients. Lifestyle, genetics, obesity, consumption of high saturated/trans fat, low thyroid levels, and kidney disease could be the cause of dyslipidaemia. Symptoms of diabetic dyslipidaemia include chest pain/tightness, indigestion, heartburn, dizziness, palpitations, shortness of breath, cold sweats, nausea, and vomiting.